Northside Hospital, Inc.
Clinical trials sponsored by Northside Hospital, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug may cut infection risk after Half-Matched stem cell transplants Results expected Sep 2026 (estimated)
- Can a simple timing change make leukemia therapy safer? Results expected Nov 2026 (estimated)
- New drug combo aims to tame transplant complication without long-term steroids Results expected Dec 2026 (estimated)
- New approach aims to tame immune storms in Half-Matched transplants Results expected Jun 2027 (estimated)
- New hope for rare blood disorder: Half-Matched transplants show promise Results expected Aug 2027 (estimated)
-
Can a Macrophage-Targeting drug supercharge CAR-T therapy?
Disease control Not yet recruitingThis trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer mor…
Phase 1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for Hard-to-Treat leukemia? early trial combines three drugs
Disease control Not yet recruitingThis early-phase trial is testing a new drug called axatilimab added to two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The study aims to find the safest dose of axatilimab and see how …
Phase 1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC